Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJFSH102
- Development stage
- Preclinical
- Lead developer
- Beijing Friendship Hospital
- Modality
- Small Molecules
01
Overview
BJFSH102 is a selective small-molecule inhibitor of microfibril-associated protein 4 (MFAP-4) under development by Beijing Friendship Hospital, Capital Medical University. It is designed to treat liver fibrosis by disrupting the interaction of MFAP-4 with extracellular matrix components, specifically elastin and collagen I. In preclinical models of carbon tetrachloride (CCl4)-induced liver fibrosis, BJFSH102 has demonstrated the ability to ameliorate fibrogenesis by preventing MFAP-4-mediated extracellular matrix stabilization and subsequent hepatic stellate cell activation.
Beyond the preview
Go deeper on BJFSH102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJFSH102.